Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer.

ABSTRACT:

SUBMITTER: Suzawa K 

PROVIDER: S-EPMC6541452 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature